Millidrop receives this funding as a laureate of the "Concours d'Innovation" (Innovation Challenge) in the health category with its project "Droplet-Based Integrated Diagnosis from Blood Culture to Antibiogram," that was backed by the Medicen Paris Région competitiveness cluster. MilliDrop's goal is to speed up the microbiological diagnosis process for patients with sepsis.
Worldwide, one person dies every 3-4 seconds from sepsis, causing between 6 and 9 m deaths every year. In industrialised nations, sepsis remains a major cause of death and is responsible for more deaths than HIV, breast cancer and prostate cancer combined.
Sepsis usually occurs following a bacterial infection which spreads to the bloodstream.
The emergence of antibiotic resistance has made it harder to treat. Administering an effective and targeted antibiotic as early as possible is crucial for patient survival and to avoid serious sequelae.
The "Concours d'Innovation" is an excellence-supporting device that operates in the digital technologies field and is financed by the Program of Investments for the Future.
This programme, which is jointly-ran by Bpifrance, ADEME and FranceAgriMer, aims to support innovative projects pursued by SMEs and start-ups.
It also aspires to nurture the emergence of world-class French champions in eight key areas: health; digital; French Fab; security and cybersecurity; transportation and sustainable mobility; renewable energies; storage and energy systems; innovation to enhance the quality of terrestrial, aquatic and marine ecosystems; innovative agriculture.
Eight projects were selected by Bpifrance in the health category for the 2018 Concours d'Innovation 's first wave.
Merck announces Phase 3 trials for once-monthly oral HIV prevention pill MK-8527
Immuno Cure and PharmaJet collaborate for novel HIV therapeutic DNA vaccine advancement
Estrella Immunopharma initiates second cohort in EB103 trial for advanced B-cell lymphomas
bioMérieux receives CE-marking for LUMED APSS to support antimicrobial stewardship in Europe
Merck reports positive Phase 3 Data on HIV treatment DOR/ISL
QOL Medical's Sucraid shows 81% effectiveness in Congenital Sucrase-Isomaltase Deficiency
Qlucore launches first CE-marked diagnostic test for paediatric leukaemia
Bruker demonstrates advancements in 4D-Proteomics at US HUPO
Mitem Pharma acquires Flisint rights from Sanofi to address rare infectious disease
Audientes partners with Audivista to expand hearing solutions in Middle East and North Africa
Benuvia Operations signs licensing deal with Avernus Pharma
Benuvia Operations signs licensing and supply agreements with Medra Brasil Medicamentos
Castle Biosciences to present data on Melanoma tests at ASDP Annual Meeting
Alchemy partners with PatchRx to improve HIV medication adherence